|Assessment Status||Rapid Review Complete|
|Indication||In combination with methotrexate, is indicated in rheumatoid arthritis for the reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.|
|Rapid review commissioned||04/03/2020|
|Rapid review completed||24/03/2020|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that infliximab SC not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.